Preimplantation Genetic Testing Market to Surpass USD 2.7 Billion by 2035 Amid Growing Demand for Advanced Reproductive Health Solutions

The preimplantation genetic testing (PGT) market is projected to witness substantial expansion in the coming decade, with the global valuation expected to reach USD 2.7 billion by 2035, up from USD 0.9 billion in 2024. This growth trajectory reflects a strong compound annual growth rate (CAGR) of 11.5%, signaling increasing adoption across fertility centers, diagnostic laboratories, and hospitals.

PGT is an evolving branch of reproductive genetics that enables genetic screening and diagnosis of embryos prior to implantation during in vitro fertilization (IVF). The rising incidence of genetic disorders, increasing maternal age, and growing awareness of IVF outcomes are key factors propelling market growth.

? Access full market details, forecasts, and sample reports:
View Full Report

Market Drivers

• Rising IVF Procedures: With global fertility rates declining and IVF becoming more common, demand for preimplantation testing to ensure healthy embryo transfer is climbing.
  
  

• Increased Genetic Disorder Awareness: Higher awareness and early screening preferences for conditions such as cystic fibrosis, Tay-Sachs disease, and chromosomal abnormalities are driving adoption.
  
  

• Technological Advancements: Improvements in NGS (Next-Generation Sequencing), PCR, and biomarker validation have enhanced test sensitivity and reduced turnaround times.
  
  

• Regulatory and Ethical Approvals: Expanding legal acceptance of genetic testing in IVF procedures across North America, Europe, and parts of Asia-Pacific is supporting global growth.
  
  

---

Key Segments

By Component:

• Product:
  
  

• Reagents & Kits
  
  

• Instruments
  
  

• Software
  
  

• Services: Increasing demand for outsourced genetic testing services is supporting market expansion.
  
  

By Procedure:

• Screening: Leading the segment, commonly used for detecting chromosomal abnormalities.
  
  

• Diagnosis: Applied for identification of specific hereditary genetic conditions.
  
  

By Technology:

• Next Generation Sequencing (NGS) – Dominates the market due to high accuracy and throughput.
  
  

• Polymerase Chain Reaction (PCR) – Preferred for rapid, cost-effective analysis.
  
  

• Fluorescent In-Situ Hybridization (FISH)
  
  

• Single Nucleotide Polymorphism
  
  

• Validation Biomarkers
  
  

• Others
  
  

By Application:

• Chromosomal Abnormalities
  
  

• X-Linked Diseases
  
  

• Embryo Testing
  
  

• Aneuploidy Screening
  
  

• HLA Typing
  
  

• Others
  
  

By End User:

• Fertility Centers – Largest consumer base driven by IVF treatments.
  
  

• Hospitals – Integrating genetic testing into reproductive health programs.
  
  

• Diagnostic Centers – Growing role in specialized, outsourced testing services.
  
  

• Others
  
  

---

Regional Insights

• North America leads global adoption, driven by technological leadership, high IVF penetration, and reimbursement coverage.
  
  

• Europe follows, especially in countries like the UK, Spain, and Denmark where IVF success rates and genetic testing are integrated.
  
  

• Asia-Pacific is emerging rapidly with expanding fertility clinics and awareness in countries such as India, China, and Japan.

Leading Industry Players

The PGT market is moderately consolidated with strong competition among key genetic and diagnostic companies. Market leaders are expanding capabilities in AI-based genetic prediction, expanding global labs, and forging partnerships with IVF clinics.

Key participants include:

• Illumina, Inc.
  
  

• Natera, Inc.
  
  

• Quest Diagnostics Incorporated
  
  

• Thermo Fisher Scientific Inc.
  
  

• Agilent Technologies, Inc.
  
  

• Invitae Corporation
  
  

• Revvity
  
  

• Fulgent Genetics
  
  

• Genea Pty Limited
  
  

• Laboratory Corporation of America Holdings
  
  

• Diagnóstica Longwood SL
  
  

• Igenomix
  
  

• Bioarray S.L.
  
  

• CooperSurgical

Outlook

As reproductive medicine embraces genetics and precision diagnostics, preimplantation genetic testing is poised to become an integral component of modern IVF protocols. With advancements in sequencing technology and global fertility awareness on the rise, the PGT sector is expected to offer significant opportunities through 2035.